Company profile
Eligo Bioscience company profile
Eligobiotics is a developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine CRISPR/Cas system with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling clients to get next-generation antimicrobials to treat diseases caused by superbugs.
Business identity
- Website
- https://eligo.bio/
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $0-$1M
- Founded
- 2014-01-01, Year
Headquarters
- Headquarters
- Plumergat, Brittany, France
- Country code
- FR
- Continent
- Europe